Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Can ultrasound be considered as a potential alternative for sentinel lymph node biopsy for axillary lymph node metastasis detection in breast cancer patients?

Farrokh D, Ameri L, Oliaee F, Maftouh M, Sadeghi M, Forghani MN, Bakhtiari E, Alamdaran SA.

Breast J. 2019 Jul 29. doi: 10.1111/tbj.13475. [Epub ahead of print] No abstract available.

PMID:
31359536
2.

Therapeutic potential of toll-like receptors in treatment of gynecological cancers.

Moradi-Marjaneh R, Hassanian SM, Hasanzadeh M, Rezayi M, Maftouh M, Mehramiz M, Ferns GA, Khazaei M, Avan A.

IUBMB Life. 2019 May;71(5):549-564. doi: 10.1002/iub.2011. Epub 2019 Feb 6. Review.

PMID:
30729633
3.

Current status and future prospects of transforming growth factor-β as a potential prognostic and therapeutic target in the treatment of breast cancer.

Amerizadeh F, Bahrami A, Khazaei M, Hesari A, Rezayi M, Talebian S, Maftouh M, Moetamani-Ahmadi M, Seifi S, Shahidsales S, Joudi-Mashhad M, Ferns GA, Ghasemi F, Avan A.

J Cell Biochem. 2019 Jan 22. doi: 10.1002/jcb.27831. [Epub ahead of print]

PMID:
30672016
4.

miRNA Targeting Angiogenesis as a Potential Therapeutic Approach in the Treatment of Colorectal Cancers.

Amerizadeh F, Khazaei M, Maftouh M, Mardani R, Bahrami A.

Curr Pharm Des. 2018;24(39):4668-4674. doi: 10.2174/1381612825666190110161843.

PMID:
30636586
5.

Association of TNF-308 G>A polymorphism located in tumor necrosis factor a with the risk of developing cervical cancer and results of pap smear.

Babapour N, Mehramiz M, Rastgar Moghadam A, Behboodi N, Yousefi Z, Maftouh M, Talebian S, Khazaei M, Jafarian A, Sharifi-Sistani N, Avan A, Hasanzadeh M.

J Cell Biochem. 2019 Apr;120(4):5444-5448. doi: 10.1002/jcb.27823. Epub 2018 Nov 1.

PMID:
30387170
6.

Therapeutic potential of targeting the Wnt/β-catenin pathway in the treatment of pancreatic cancer.

Javadinia SA, Shahidsales S, Fanipakdel A, Joudi-Mashhad M, Mehramiz M, Talebian S, Maftouh M, Mardani R, Hassanian SM, Khazaei M, Ferns GA, Avan A.

J Cell Biochem. 2018 Oct 28. doi: 10.1002/jcb.27835. [Epub ahead of print] Review.

PMID:
30368889
7.

Relationship between platelet count and platelet width distribution and serum uric acid concentrations in patients with untreated essential hypertension.

Tayefi M, Hassanian SM, Maftouh M, Moohebati M, Bahrami A, Parizadeh SM, Mahdizadeh A, Ghazizadeh H, Bazeli J, Heidari-Bakavoli A, Kianifar H, Mohammadzadeh E, Rahmani F, Esmaeili H, Ebrahimi M, Azarpazhooh MR, Nematy M, Safarian M, Ferns GA, Avan A, Ghayour-Mobarhan M.

Biofactors. 2018 Nov;44(6):532-538. doi: 10.1002/biof.1453. Epub 2018 Sep 27.

PMID:
30260522
8.

Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer.

Beheshti F, Hassanian SM, Khazaei M, Hosseini M, ShahidSales S, Hasanzadeh M, Maftouh M, Ferns GA, Avan A.

J Cell Physiol. 2018 Apr;233(4):2752-2758. doi: 10.1002/jcp.26091. Epub 2017 Aug 30. Review.

PMID:
28696006
9.

The Therapeutic Potential of Targeting Tumor Microenvironment in Breast Cancer: Rational Strategies and Recent Progress.

Bahrami A, Hassanian SM, Khazaei M, Hasanzadeh M, Shahidsales S, Maftouh M, Ferns GA, Avan A.

J Cell Biochem. 2018 Jan;119(1):111-122. doi: 10.1002/jcb.26183. Epub 2017 Jul 4. Review.

PMID:
28574616
10.

Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress.

Bahrami A, Khazaei M, Hassanian SM, ShahidSales S, Joudi-Mashhad M, Maftouh M, Jazayeri MH, Parizade MR, Ferns GA, Avan A.

J Cell Physiol. 2018 Apr;233(4):2928-2936. doi: 10.1002/jcp.26041. Epub 2017 Jun 30. Review.

PMID:
28574572
11.

Genetic Background of Hirschsprung Disease: A Bridge Between Basic Science and Clinical Application.

Bahrami A, Joodi M, Moetamani-Ahmadi M, Maftouh M, Hassanian SM, Ferns GA, Avan A.

J Cell Biochem. 2018 Jan;119(1):28-33. doi: 10.1002/jcb.26149. Epub 2017 Jun 27. Review.

PMID:
28543993
12.

Genetic susceptibility in cervical cancer: From bench to bedside.

Bahrami A, Hasanzadeh M, Shahidsales S, Farazestanian M, Hassanian SM, Moetamani Ahmadi M, Maftouh M, Gharib M, Yousefi Z, Kadkhodayan S, Ferns GA, Avan A.

J Cell Physiol. 2018 Mar;233(3):1929-1939. doi: 10.1002/jcp.26019. Epub 2017 Sep 7. Review.

PMID:
28542881
13.

The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.

Bahrami A, Khazaei M, Shahidsales S, Hassanian SM, Hasanzadeh M, Maftouh M, Ferns GA, Avan A.

J Cell Biochem. 2018 Jan;119(1):213-222. doi: 10.1002/jcb.26136. Epub 2017 Jul 4. Review.

PMID:
28513879
14.

Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.

Bahrami A, Amerizadeh F, Hassanian SM, ShahidSales S, Khazaei M, Maftouh M, Ghayour-Mobarhan M, Ferns GA, Avan A.

J Cell Physiol. 2018 Mar;233(3):2193-2201. doi: 10.1002/jcp.25966. Epub 2017 May 23. Review.

PMID:
28422287
15.

Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer.

Bahrami A, Hassanian SM, ShahidSales S, Farjami Z, Hasanzadeh M, Anvari K, Aledavood A, Maftouh M, Ferns GA, Khazaei M, Avan A.

J Cell Physiol. 2018 Mar;233(3):2058-2066. doi: 10.1002/jcp.25890. Epub 2017 May 23. Review.

PMID:
28262927
16.

Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress.

Bahrami A, Khazaei M, Hasanzadeh M, ShahidSales S, Joudi Mashhad M, Farazestanian M, Sadeghnia HR, Rezayi M, Maftouh M, Hassanian SM, Avan A.

J Cell Biochem. 2018 Mar;119(3):2460-2469. doi: 10.1002/jcb.25950. Epub 2017 May 15. Review.

PMID:
28230287
17.

Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer.

Ebrahimi S, Hosseini M, Shahidsales S, Maftouh M, Ferns GA, Ghayour-Mobarhan M, Hassanian SM, Avan A.

Curr Med Chem. 2017;24(13):1321-1331. doi: 10.2174/0929867324666170206142658. Review.

PMID:
28176634
18.

Current Status and Perspectives Regarding the Therapeutic Potential of Targeting EGFR Pathway by Curcumin in Lung Cancer.

Shafiee M, Mohamadzade E, ShahidSales S, Khakpouri S, Maftouh M, Parizadeh SA, Hasanian SM, Avan A.

Curr Pharm Des. 2017;23(13):2002-2008. doi: 10.2174/1381612823666170123143648. Review.

PMID:
28117012
19.

Therapeutic Potential of Targeting Wnt/β-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress.

Bahrami A, Amerizadeh F, ShahidSales S, Khazaei M, Ghayour-Mobarhan M, Sadeghnia HR, Maftouh M, Hassanian SM, Avan A.

J Cell Biochem. 2017 Aug;118(8):1979-1983. doi: 10.1002/jcb.25903. Epub 2017 Apr 25. Review.

PMID:
28109136
20.

The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs.

Bahrami A, Aledavood A, Anvari K, Hassanian SM, Maftouh M, Yaghobzade A, Salarzaee O, ShahidSales S, Avan A.

J Cell Physiol. 2018 Feb;233(2):774-786. doi: 10.1002/jcp.25813. Epub 2017 Mar 24. Review.

PMID:
28109133
21.

Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives.

Hosseini M, Hassanian SM, Mohammadzadeh E, ShahidSales S, Maftouh M, Fayazbakhsh H, Khazaei M, Avan A.

J Cell Biochem. 2017 Jul;118(7):1634-1638. doi: 10.1002/jcb.25897. Epub 2017 Mar 15. Review.

PMID:
28106283
22.

Targeting stroma in pancreatic cancer: Promises and failures of targeted therapies.

Bahrami A, Khazaei M, Bagherieh F, Ghayour-Mobarhan M, Maftouh M, Hassanian SM, Avan A.

J Cell Physiol. 2017 Nov;232(11):2931-2937. doi: 10.1002/jcp.25798. Epub 2017 Mar 31. Review.

PMID:
28083912
23.

C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.

Bahrami A, Shahidsales S, Khazaei M, Ghayour-Mobarhan M, Maftouh M, Hassanian SM, Avan A.

J Cell Physiol. 2017 Oct;232(10):2657-2673. doi: 10.1002/jcp.25794. Epub 2017 Apr 10. Review.

PMID:
28075018
24.

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.

Massihnia D, Avan A, Funel N, Maftouh M, van Krieken A, Granchi C, Raktoe R, Boggi U, Aicher B, Minutolo F, Russo A, Leon LG, Peters GJ, Giovannetti E.

J Hematol Oncol. 2017 Jan 6;10(1):9. doi: 10.1186/s13045-016-0371-1.

25.

Exosome-Encapsulated microRNAs as Potential Circulating Biomarkers in Colon Cancer.

Hosseini M, Khatamianfar S, Hassanian SM, Nedaeinia R, Shafiee M, Maftouh M, Ghayour-Mobarhan M, ShahidSales S, Avan A.

Curr Pharm Des. 2017;23(11):1705-1709. doi: 10.2174/1381612822666161201144634. Review.

PMID:
27908272
26.

Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.

Ebrahimi S, Hosseini M, Ghasemi F, Shahidsales S, Maftouh M, Akbarzade H, Parizadeh SA, Hassanian SM, Avan A.

Curr Pharm Des. 2016;22(42):6444-6450. doi: 10.2174/1381612822666160817095047. Review.

PMID:
27539232
27.

Circulating microRNAs as Potential Diagnostic Biomarkers and Therapeutic Targets in Gastric Cancer: Current Status and Future Perspectives.

Mirzaei H, Khataminfar S, Mohammadparast S, Sales SS, Maftouh M, Mohammadi M, Simonian M, Parizadeh SM, Hassanian SM, Avan A.

Curr Med Chem. 2016;23(36):4135-4150.

PMID:
27538692
28.

The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications.

Tajbakhsh A, Khorrami MS, Hassanian SM, Aghasizade M, Pasdar A, Maftouh M, Tabatabai E, Parizadeh SM, Fazeli M, Ferns GA, Ghayour-Mobarhan M, Avan A.

Curr Pharm Des. 2016;22(37):5730-5737. Review.

PMID:
27356775
29.

Lack of BRAFV600E mutation in stage I and II of colorectal cancer.

Molaei M, Kishani Farahani R, Maftouh M, Taleghani MY, Vahdatinia M, Khatami F, Nazemalhosseini-Mojarad E, Asadzadeh Aghdae H, Aboutorabi A, Zali MR.

Gastroenterol Hepatol Bed Bench. 2016 Spring;9(2):94-9.

30.

Biomarker Analysis in CLEOPATRA: Searching for a Sensitive Prognostic Factor in Breast Cancer.

Avan A, Avan A, Maftouh M, Ghayour Mobarhan M, Shahidsales S, Gholamin S.

J Clin Oncol. 2015 May 20;33(15):1711-2. doi: 10.1200/JCO.2014.60.4702. Epub 2015 Apr 13. No abstract available.

PMID:
25870088
31.

Pharmacogenomic modeling in pancreatic cancer—letter.

Avan A, Avan A, Maftouh M, Mobarhan MG, Gholamin S.

Clin Cancer Res. 2015 Mar 15;21(6):1497. doi: 10.1158/1078-0432.CCR-14-2951. No abstract available.

32.

Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.

Gholamin S, Fiuji H, Maftouh M, Mirhafez R, Shandiz FH, Avan A.

Curr Drug Targets. 2014;15(14):1302-11. Review.

PMID:
25382190
33.

AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients.

Avan A, Avan A, Le Large TY, Mambrini A, Funel N, Maftouh M, Ghayour-Mobarhan M, Cantore M, Boggi U, Peters GJ, Pacetti P, Giovannetti E.

PLoS One. 2014 Sep 19;9(9):e108057. doi: 10.1371/journal.pone.0108057. eCollection 2014.

34.

Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcinoma.

Maftouh M, Belo AI, Avan A, Funel N, Peters GJ, Giovannetti E, Van Die I.

Oncotarget. 2014 Jul 30;5(14):5335-49.

35.

miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.

Maftouh M, Avan A, Funel N, Frampton AE, Fiuji H, Pelliccioni S, Castellano L, Galla V, Peters GJ, Giovannetti E.

Nucleosides Nucleotides Nucleic Acids. 2014;33(4-6):384-93. doi: 10.1080/15257770.2014.891741.

PMID:
24940696
36.

SNPs in PI3K-PTEN-mTOR and brain metastases in NSCLC--letter.

Avan A, Maftouh M, Avan A, Tibaldi C, Zucali PA, Giovannetti E.

Clin Cancer Res. 2014 Jul 1;20(13):3623-4. doi: 10.1158/1078-0432.CCR-13-3256. Epub 2014 May 6. No abstract available.

37.

A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.

Maftouh M, Avan A, Funel N, Paolicchi E, Vasile E, Pacetti P, Vaccaro V, Faviana P, Campani D, Caponi S, Mambrini A, Boggi U, Cantore M, Milella M, Peters GJ, Reni M, Giovannetti E.

Pharmacogenomics. 2014 Apr;15(5):609-18. doi: 10.2217/pgs.13.225.

PMID:
24798718
38.

Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.

Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, Funel N, Smid K, Honeywell R, Boggi U, Minutolo F, Peters GJ, Giovannetti E.

Br J Cancer. 2014 Jan 7;110(1):172-82. doi: 10.1038/bjc.2013.681. Epub 2013 Oct 31.

39.

Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.

Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, Lagerweij T, Van Tellingen O, Campani D, Fuchs D, Verheul HM, Schuurhuis GJ, Boggi U, Peters GJ, Würdinger T, Giovannetti E.

Cancer Res. 2013 Nov 15;73(22):6745-56. doi: 10.1158/0008-5472.CAN-13-0837. Epub 2013 Oct 1.

40.

MET as a potential target for the treatment of upper gastrointestinal cancers: characterization of novel c-Met inhibitors from bench to bedside.

Avan A, Maftouh M, Funel N, Ghayour-Mobarhan M, Boggi U, Peters GJ, Giovannetti E.

Curr Med Chem. 2014;21(8):975-89. Review.

PMID:
23992325
43.

Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.

Avan A, Quint K, Nicolini F, Funel N, Frampton AE, Maftouh M, Pelliccioni S, Schuurhuis GJ, Peters GJ, Giovannetti E.

Curr Pharm Des. 2013;19(5):940-50.

PMID:
22973962
44.

CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus.

Béquet F, Uzabiaga F, Desbazeille M, Ludwiczak P, Maftouh M, Picard C, Scatton B, Le Fur G.

Eur J Neurosci. 2007 Dec;26(12):3458-64. Epub 2007 Dec 4.

PMID:
18052990
45.
46.

Screening approach for chiral separation of pharmaceuticals IV. Polar organic solvent chromatography.

Matthijs N, Maftouh M, Heyden YV.

J Chromatogr A. 2006 Apr 7;1111(1):48-61. Epub 2006 Feb 17.

PMID:
16483582
47.

Strategy for the chiral separation of non-acidic pharmaceuticals using capillary electrochromatography.

Mangelings D, Discry J, Maftouh M, Massart DL, Vander Heyden Y.

Electrophoresis. 2005 Oct;26(20):3930-41.

PMID:
16167306
48.

Screening approach for chiral separation of pharmaceuticals. Part III. Supercritical fluid chromatography for analysis and purification in drug discovery.

Maftouh M, Granier-Loyaux C, Chavana E, Marini J, Pradines A, Heyden YV, Picard C.

J Chromatogr A. 2005 Sep 23;1088(1-2):67-81.

PMID:
16130734
49.

Capillary electrochromatographic chiral separations with potential for pharmaceutical analysis.

Mangelings D, Maftouh M, Vander Heyden Y.

J Sep Sci. 2005 May;28(8):691-709.

PMID:
15938179
50.

Separation strategy for acidic chiral pharmaceuticals with capillary electrochromatography on polysaccharide stationary phases.

Mangelings D, Tanret I, Matthijs N, Maftouh M, Massart DL, Vander Heyden Y.

Electrophoresis. 2005 Feb;26(4-5):818-32.

PMID:
15714567

Supplemental Content

Loading ...
Support Center